RAPIBLYK
GrowthSMlandiolol
NDAINTRAVENOUSPOWDER
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 15h ago · AI intelligence enriched 17h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RAPIBLYK (landiolol) is an intravenous ultra-short-acting beta-1 selective adrenergic antagonist approved November 2024. It is indicated for acute heart rate management in perioperative and critical care settings. The drug works by rapidly blocking beta-1 adrenergic receptors to reduce heart rate with a quick onset and offset profile suitable for IV administration.
Growth7.5 years to LOE
As a newly approved IV acute-care product in growth phase with no identified direct competitors, the brand team will focus on rapid market penetration and hospital formulary adoption.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This newly launched IV acute-care product offers career opportunities in hospital-focused commercial roles, particularly field sales and MSL positions targeting ICU, OR, and critical care settings. With zero identified competitors and a 7.5-year patent runway, roles will emphasize rapid formulary adoption, hospital account management, and clinical evidence building.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.